Thrixen
Thrixen is a biotechnology company founded in 2021 by international scientists from Singapore and the USA, originating from SMART (Singapore MIT Alliance for Research and Technology). The company specializes in proprietary technologies that revolutionize biomarker detection and rapid assay generation, enabling diagnostics to be more accessible, affordable, and scalable. Thrixen develops a diagnostic technology platform that makes diagnostics available when and where they matter most, utilizing engineered protein binders and a unique assay format to bring essential diagnostics closer to patients.
Industries
Nr. of Employees
small (1-50)
Products
Multiplex point-of-care diagnostic platform
A platform designed to perform rapid, multiplex diagnostic tests on whole blood at the point of care using engineered protein binders and compatible assay formats.
Rapid neutralizing-antibody serology test (research/preprint)
A rapid finger-stick blood test format developed to assess post-vaccination neutralizing antibody response against SARS-CoV-2 variants (reported in preprint and peer-reviewed outlets).
Multiplex point-of-care diagnostic platform
A platform designed to perform rapid, multiplex diagnostic tests on whole blood at the point of care using engineered protein binders and compatible assay formats.
Rapid neutralizing-antibody serology test (research/preprint)
A rapid finger-stick blood test format developed to assess post-vaccination neutralizing antibody response against SARS-CoV-2 variants (reported in preprint and peer-reviewed outlets).
Services
Custom assay development for infectious diseases
R&D collaborations to design and develop rapid, multiplex point-of-care assays for infectious-disease targets, including whole-blood formats.
Protein binder engineering and selection
Design and screening of engineered protein binders to replace conventional antibodies as affinity reagents in diagnostic assays.
Assay reader integration and image-analysis software
Integration of assays with reader hardware and development of image-analysis software for automated result interpretation.
Assay verification and validation support
Verification and validation activities to establish assay performance prior to clinical evaluation or regulatory submission.
Custom assay development for infectious diseases
R&D collaborations to design and develop rapid, multiplex point-of-care assays for infectious-disease targets, including whole-blood formats.
Protein binder engineering and selection
Design and screening of engineered protein binders to replace conventional antibodies as affinity reagents in diagnostic assays.
Assay reader integration and image-analysis software
Integration of assays with reader hardware and development of image-analysis software for automated result interpretation.
Assay verification and validation support
Verification and validation activities to establish assay performance prior to clinical evaluation or regulatory submission.
Expertise Areas
- Point-of-care diagnostics
- Protein engineering and binder selection
- Multiplex assay development
- Biosensor design
Key Technologies
- Engineered protein binders (non-antibody affinity reagents)
- Multiplex point-of-care assay formats
- Paper-based diagnostic devices
- Microfluidics